Universal Autism Genes: New Research Shows Autism Risk Genes Shared Across Ancestries

Understanding the Genetic Foundations of Autism Spectrum Disorder

Autism Spectrum Disorder (ASD), a complex neurodevelopmental condition characterized by challenges with social interaction, communication, and repetitive and restricted behaviors, affects approximately 1 in 36 children in the United States according to the latest Centers for Disease Control and Prevention data. Globally, the prevalence is estimated at around 1 in 100 children, with variations due to diagnostic practices and awareness levels. The etiology of ASD is multifaceted, involving a combination of genetic and environmental factors, but research consistently points to genetics as the predominant contributor, accounting for up to 80% of the risk based on twin and family studies conducted over decades.

Deleterious coding variants—rare genetic changes in protein-coding regions that disrupt normal function—play a critical role in ASD risk. These variants often occur in highly conserved genes, meaning genes that have remained similar across species over evolutionary time, suggesting their essential functions in brain development. Historically, genomic studies have identified over 1,000 genes implicated in ASD, with around 100 showing strong evidence from large-scale sequencing efforts. However, a significant challenge has been the underrepresentation of non-European ancestries in these datasets, leading to potential biases in gene discovery and clinical applications.

The Challenge of Ancestry Bias in Autism Genomics

Prior large-scale exome sequencing studies, such as those from the Simons Foundation Autism Research Initiative and the Autism Sequencing Consortium, have predominantly drawn from cohorts of European ancestry. This has resulted in a catalog of ASD risk genes that may not fully generalize to other populations. For instance, polygenic risk scores derived from European data often perform poorly in individuals of African or Latin American descent, leading to inequities in genetic diagnosis and counseling.

Latin American populations, with their unique admixture of Indigenous American, European, West African, and other ancestries, represent an ideal group to test the universality of these findings. Admixed populations like these provide a natural experiment to disentangle ancestry-specific effects from shared biological mechanisms. The need for diverse cohorts has been emphasized by experts, as limited ancestral diversity in reference datasets can skew evolutionary conservation metrics, potentially overestimating the constraint on certain genes.

Introducing the GALA Study: A Landmark Effort in Diverse Autism Research

The Genomics of Autism in Latinx Ancestries (GALA) study emerges as one of the most ambitious efforts to address this gap. Spearheaded by collaborative teams across North, Central, and South America, GALA has collected genetic data from over 15,000 individuals, including about 4,700 diagnosed with ASD. This cohort spans diverse collection sites, capturing the rich genetic mosaic of Latin American heritage.

At the Icahn School of Medicine at Mount Sinai, researchers have played a pivotal role in analyzing this data. The Seaver Autism Center for Research and Treatment, under the direction of Joseph D. Buxbaum, PhD, has a storied history in ASD genomics, having contributed to identifying over 100 high-confidence risk genes in previous multinational efforts. GALA builds on this foundation, employing whole-exome sequencing to scrutinize more than 18,000 protein-coding genes for rare, damaging variants.

Methodology: Rigorous Analysis of Rare Coding Variants

The study's approach involved burden testing, a statistical method that aggregates the effects of rare variants within genes to detect enrichment in ASD cases versus controls. Researchers focused on loss-of-function variants and other deleterious changes predicted to impair protein function, prioritizing genes under strong evolutionary constraint (e.g., those with high probability of loss-of-function intolerance scores).

Step-by-step, the process unfolded as follows:

• Sequencing and quality control of exome data from GALA participants.
• Annotation of variants using tools like gnomAD for population frequency and REVEL for pathogenicity.
• Burden analysis stratified by ancestry components to account for admixture.
• Comparison with large European-ancestry datasets from prior genome-wide association studies.

This methodical framework ensured robust detection of signals, mitigating confounding from population structure.

Key Findings: 35 Genes and Extensive Overlap Across Ancestries

The analysis yielded 35 genome-wide significant ASD-associated genes in the Latin American cohort, a testament to the power of large-scale diverse sequencing. Remarkably, these genes exhibited extensive overlap with those pinpointed in European-ancestry studies, affirming that the core genetic architecture of autism transcends ancestral boundaries.

Furthermore, the study corroborated several "emerging" genes recently proposed in smaller datasets, strengthening the ASD gene catalog. Rare deleterious variants were disproportionately enriched in highly conserved genes among ASD cases, mirroring patterns observed globally. While conservation metrics derived from European data may slightly overestimate constraint for less conserved genes, they proved reliable for the ultra-constrained ones most relevant to ASD.

These results, detailed in the Nature Medicine publication, underscore a universal biology for autism risk.5958

Implications for Clinical Diagnosis and Precision Medicine

The shared genetic signals have profound implications for clinical practice. Genetic testing panels for ASD can now be applied more confidently across ancestries, potentially increasing diagnostic yields for non-European patients who previously faced inconclusive results. For families, this means earlier identification, tailored interventions, and informed reproductive counseling.

In precision medicine, refined polygenic risk scores incorporating diverse data could predict ASD liability more accurately, guiding early screening in high-risk groups. The study also highlights opportunities for gene-specific therapies, such as antisense oligonucleotides for haploinsufficient genes, applicable universally.As noted in the press release, this roadmap promises to bridge health disparities.

Mount Sinai's Enduring Contributions to Autism Research

The Icahn School of Medicine at Mount Sinai stands at the forefront of this progress. Director Buxbaum's team has led multiple landmark studies, including the identification of 102 ASD genes in 2020 and analyses implicating shared risk with other neurodevelopmental disorders. The Seaver Center integrates genomics with clinical care, training the next generation of researchers.

This work exemplifies higher education's role in tackling global health challenges through interdisciplinary collaboration. Faculty and students at institutions like Mount Sinai drive discoveries that inform policy, education, and careers in neuroscience and genetics.

Broader Impacts on Neurodevelopmental Disorders and Equity

Beyond ASD, the findings extend to related conditions like schizophrenia and intellectual disability, where overlapping genetic risks are evident. By validating European-derived tools in admixed populations, the study paves the way for equitable genomics worldwide.

Stakeholder perspectives vary: Clinicians advocate for updated testing guidelines, families seek accessible diagnostics, and policymakers emphasize funding for diverse biobanks. Real-world examples include improved outcomes in Latin American clinics adopting expanded panels, reducing diagnostic odysseys.

Challenges and Future Directions in Cross-Ancestry Genomics

Despite advances, hurdles remain: Smaller effect sizes in non-European cohorts require even larger samples, and African/Asian ancestries need similar scrutiny. Future efforts should integrate multi-omics data (e.g., transcriptomics, epigenomics) for functional insights.

• Expand GALA-like initiatives to underrepresented regions.
• Develop ancestry-agnostic risk prediction models.
• Foster international training programs for genomic researchers.
• Invest in community-engaged biobanking.

Dr. Buxbaum emphasizes: “Expanding genomic research in underrepresented populations is essential to reducing health disparities.”This vision guides the field forward.

Actionable Insights for Researchers, Educators, and Families

For academics pursuing careers in genomics, this study highlights opportunities in diverse cohort analysis and computational biology. Explore positions in university research centers focusing on neurogenetics to contribute to such breakthroughs.

Educators can incorporate these findings into curricula, emphasizing inclusive science. Families benefit from advocacy for diverse genetic databases, ensuring personalized ASD support. Timelines suggest clinical translation within 2-5 years, with ongoing trials for gene therapies.

Photo by Ekke Krosing on Unsplash

Looking Ahead: A Unified Understanding of Autism Genetics

This Mount Sinai-led research heralds a new era where autism's genetic roots are seen as fundamentally human, not ancestry-bound. By championing diversity, higher education institutions continue to illuminate paths to better outcomes for millions worldwide.